All In Biotech

Drug Trial Radar · NCT06560489

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

Clinical Trial of Safety, Pharmacodynamics and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Primary Treatment of HIV-infected Patients

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 2, 2024

Primary completion

Jan 10, 2025

Study completion Aug 22, 2025

Sponsor

Sponsor type
Industry
Collaborators
Institute of Pathogen Biology, Beijing, China
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive HIV-Infected Individuals

Conditions

  • Hiv

Interventions

  • Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.Drug

    This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from baseline in respiration rate of Vital Signs.Time frame: Within 71 days after the first administration.
  2. Changes from baseline in blood pressure of Vital Signs.Time frame: Within 71 days after the first administration.
  3. Changes from baseline in Blood lactate of Laboratory Examination.Time frame: Within 71 days after the first administration.
  4. Changes from baseline in body temperature of Vital Signs.Time frame: Within 71 days after the first administration.
  5. Changes from baseline in red blood cell count of Laboratory Examination.Time frame: Within 71 days after the first administration.
  6. Changes from baseline in white blood cell count of Laboratory Examination.Time frame: Within 71 days after the first administration.
  7. Changes from baseline in neutrophil count of Laboratory Examination.Time frame: Within 71 days after the first administration.
  8. Changes from baseline in lymphocyte count of Laboratory Examination.Time frame: Within 71 days after the first administration.
  9. Changes from baseline in platelet count of Laboratory Examination.Time frame: Within 71 days after the first administration.
  10. Changes from baseline in hemoglobin of Laboratory Examination.Time frame: Within 71 days after the first administration.
  11. Changes from baseline in PT of Laboratory Examination.Time frame: Within 71 days after the first administration.
  12. Changes from baseline in INR of Laboratory Examination.Time frame: Within 71 days after the first administration.
  13. Changes from baseline in APTT of Laboratory Examination.Time frame: Within 71 days after the first administration.
  14. Changes from baseline in total bilirubin of Laboratory Examination.Time frame: Within 71 days after the first administration.
  15. Changes from baseline in direct bilirubin of Laboratory Examination.Time frame: Within 71 days after the first administration.
  16. Changes from baseline in ALT of Laboratory Examination.Time frame: Within 71 days after the first administration.
  17. Changes from baseline in AST of Laboratory Examination.Time frame: Within 71 days after the first administration.
  18. Changes from baseline in total protein of Laboratory Examination.Time frame: Within 71 days after the first administration.
  19. Changes from baseline in albumin of Laboratory Examination.Time frame: Within 71 days after the first administration.
  20. Changes from baseline in urea of Laboratory Examination.Time frame: Within 71 days after the first administration.
  21. Changes from baseline in creatinine of Laboratory Examination.Time frame: Within 71 days after the first administration.
  22. Changes from baseline in uric acid of Laboratory Examination.Time frame: Within 71 days after the first administration.
  23. Changes from baseline in glucose of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  24. Changes from baseline in potassium of Laboratory Examination.Time frame: Within 71 days after the first administration.
  25. Changes from baseline in sodium of Laboratory Examination.Time frame: Within 71 days after the first administration.
  26. Changes from baseline in chlorine of Laboratory Examination.Time frame: Within 71 days after the first administration.
  27. Changes from baseline in urine specific gravity of Laboratory Examination.Time frame: Within 71 days after the first administration.
  28. Changes from baseline in urine pH of Laboratory Examination.Time frame: Within 71 days after the first administration.
  29. Changes from baseline in urine glucose of Laboratory Examination.Time frame: Within 71 days after the first administration.
  30. Changes from baseline in urine protein of Laboratory Examination.Time frame: Within 71 days after the first administration.
  31. Changes from baseline in urine ketone body of Laboratory Examination.Time frame: Within 71 days after the first administration.
  32. Changes from baseline in urine white blood cell of Laboratory Examination.Time frame: Within 71 days after the first administration.
  33. Changes from baseline in urine bilirubin of Laboratory Examination.Time frame: Within 71 days after the first administration.
  34. Changes from baseline in urine occult blood of Laboratory Examination.Time frame: Within 71 days after the first administration.
  35. Changes from baseline in Electrocardiogram.Time frame: Within 71 days after the first administration.
  36. Changes from baseline in CK of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  37. Changes from baseline in CK-MB of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  38. Changes from baseline in LDH of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  39. Changes from baseline in ALP of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  40. Changes from baseline in Triglyceride of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  41. Changes from baseline in CHOL of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  42. Changes from baseline in TP of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  43. Changes from baseline in ALB of Laboratory ExaminationTime frame: Within 71 days after the first administration.
  44. Changes from baseline in UA of Laboratory ExaminationTime frame: Within 71 days after the first administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.